NCT01486446View on ClinicalTrials.gov

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

May 31, 2012

Conditions
Primary ErythromelalgiaInherited Erythromelalgia
Interventions
DRUG

XPF-002

XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days

DRUG

Placebo

XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.

Trial Locations (1)

36201

Pinnacle Research Group, LLC., Anniston

All Listed Sponsors
lead

Xenon Pharmaceuticals Inc.

INDUSTRY

NCT01486446 - Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia | Biotech Hunter | Biotech Hunter